


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: September 13, 2002

Signature: *Sharon M. Sirtich*

(Sharon M. Sirtich)

1646 1600 0590
Docket No.: 28110/36737
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Asundi et al.

Application No.: 09/687,860

Filed: October 13, 2000

Group Art Unit: To be determined

Projected Examiner: To be determined

For: EGF MOTIF PROTEIN, EGFL6
MATERIALS AND METHODS

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Submitted herewith is a Form PTO-1449 listing several documents. Copies of documents A1-A2, B1-B5 and C1-C7 have been submitted in the parent application no. 09/363,316, filed July 28, 1999 and pursuant to 37 CFR §1.98(d), copies are not submitted herewith. Copies of documents C8-C16 are submitted herewith.

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 USC §102 or §103.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed to be due under 37 CFR §1.97 (b) because this statement and Form PTO-1449 are being submitted before receipt of a first office action on the merits in the above-identified patent application. However, the Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: September 13, 2002

Respectfully submitted,

By 
Sharon M. Sintich
Registration No.: 48,484
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicant